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Abstract 
Being overweight or obese is associated with an increased risk for the development of 
non-insulin-dependent  diabetes  mellitus,  hypertension,  and  cardiovascular  disease. 
Dyslipidemia of obesity is characterized by elevated fasting triglycerides and decreased 
high-density lipoprotein-cholesterol concentrations.  Endothelial damage and dysfunc-
tion is considered to be a major underlying mechanism for the elevated cardiovascular 
risk  associated  with  increased  adiposity.  Alterations  in  endothelial  cells  and 
stem/endothelial progenitor cell function associated with overweight and obesity pre-
dispose to atherosclerosis and thrombosis.  
In our study, we analyzed the effect of a low calorie diet in combination with oral sup-
plementation  by  vitamins,  minerals,  probiotics  and  human  chorionic  gonadotropin 
(hCG, 125-180 IUs) on the body composition, lipid profile and CD34-positive cells in 
circulation.  
 During this dieting program, the following parameters were assessed weekly for all 
participants: fat free mass, body fat, BMI, extracellular/intracellular water, total body 
water and basal metabolic rate. For part of participants blood chemistry parameters and 
circulating CD34-positive cells were determined before and after dieting.  
 The data indicated that the treatments not only reduced body fat mass and total mass 
but also improved the lipid profile. The changes in body composition correlated with the 
level  of  lipoproteins  responsible  for  the  increased  cardiovascular  risk  factors.  These 
changes in body composition and lipid profile parameters coincided with the improve-
ment of circulatory progenitor cell numbers.  
As the result of our study, we concluded that the improvement of body composition af-
fects the number of stem/progenitor cells in circulation. 
Key words: weight reduction, body composition, cardiovascular risk factors, lipid profile, progen-
itor cells. 
Introduction 
Living in an environment characterized by calo-
rie-rich  foods  and  low  physical  activity,  over  two 
thirds of Americans are overweight [1]. This is a major 
public  health  problem,  as  obesity  predisposes  to  a 
variety of age-related inflammatory diseases, includ-
ing insulin resistance, type 2 diabetes, atherosclerosis 
and its complications, fatty liver diseases, osteoarthri-
tis,  rheumatoid  arthritis,  and  cancer  [2-4].  Clinical 
studies  have  identified  a  relationship  between  in-
creased body weight and cardiovascular disease in-
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cluding  coronary  atherosclerosis,  congestive  heart 
failure, arrhythmias, and stroke [5-11].  
In  addition  to  established  cardiovascular  risk 
factors,  systemic  inflammation,  increased  oxidative 
stress,  and  altered  hemodynamics  associated  with 
excess weight may directly contribute to endothelial 
injury and dysfunction [12]. Progenitor cells,  which 
are released from the bone marrow are sensitive to 
oxidative stress [13-16]. Circulating endothelial pro-
genitor  cell  (EPC)  numbers  have  been  found  to  be 
lower  in  obese  subjects  compared  to  overweight  or 
normal weight adults, and the colony-forming capac-
ity of these cells is blunted [17, 18]. Alterations in en-
dothelial cells and EPC function associated with obe-
sity  precede  atherosclerosis  and  thrombosis  [19-21]. 
Moreover,  EPCs  expanded  from  the  obese  subjects 
possessed  reduced  adhesive,  migratory,  and  angio-
genic  capacity  [22]  and  fail  to  respond  to  vascular 
endothelial  growth  factor.  Mice  treated  with  obese 
EPCs exhibited reduced EPC homing in ischemic hind 
limbs in vivo.  
Etiology of obesity is complex, involving inter-
related  biochemical,  neurological  physiological,  ge-
netic, environmental, cultural and psychological fac-
tors. Adipose tissue can be considered as an endocrine 
organ that mediates biological effects on the metabo-
lism  and  inflammation,  contributing  to  the  mainte-
nance of energy homeostasis and the pathogenesis of 
obesity-related  metabolic  and  inflammatory  compli-
cations  [4].  Endothelial  damage  and  dysfunction  is 
considered to be a major underlying mechanism for 
the  heightened  cardiovascular  burden  that  occurs 
with increased adiposity.  
The goal of our study was to examine how car-
diovascular risk factors and circulating CD34-positive 
cell numbers correlate when overweight subjects at-
tempt to lose weight through calorie restriction. The 
particular weight loss regimen we examined consisted 
of severe calorie restriction along with vitamin sup-
plements  and  administration  of  human  chorionic 
gonadotropin  (hCG),  a  hormone  that  encourages 
metabolic utilization of visceral fat reserves [23-26].  
Materials and Methods 
Weight Loss Protocol 
Our study consisted  of fifty three participants, 
eighty  percent  of  which  were  women, with  ages 
ranging from 26 to 63. The starting body mass index 
of  these  subjects  ranged  from  30  to  67,  while  their 
body fat percentage ranged from 15% to 48% when 
they  began  treatment.  All  subjects  gave  written  in-
formed  consent  (as  per  Helsinki  Declaration  guide-
lines) and underwent the dietary program with the 
oversight of their primary care physician. Although, 
the program mainly aimed at overweight and obese 
people, it was open to anyone interested.  
The weight loss program consisted of a 500 calo-
rie per day dietary restriction in combination with the 
following: 
1.  Daily sublingual treatments by vitamin B12 
(1,000 g per day). 
2.  Oral supplements consisting of the following 
nutrients:  250  mg  tyrosine,  2  mg  -glucan, 
200 g selenium, 1 mg folic acid, 5 mg io-
dine,  7.5  mg  potassium  iodide,  600  mg 
magnesium,  5  g  vitamin  D3,  60  mg  coen-
zyme Q10, 150 mg lipoic acid, 340 mg ace-
tyl-l-carnitine,  100  mg  vitamin  B  complex, 
and  a  probiotic  (2  billion  CFU  acidophilus 
with 2 billion CFU bifidus and 109 mg FOS). 
3.  Daily  treatments  of  hCG  nasal  spray,  at 
doses of 125 – 180 IU. 
The very low calorie diet can be summarized as 
follows:  breakfast  consisted  of  coffee/tea  with  no 
sugar  or  one  fruit  serving,  while  lunch  and  dinner 
each  consisted  of  3.5  oz  lean  protein,  a  vegetable 
serving, bread serving, and a fruit serving. The pro-
gram schedule was as follows: patients took supple-
ments, B12, and hCG for two days prior to beginning 
a 36-day very low calorie diet. This was followed by a 
35 day maintenance period during which calorie in-
take was gradually raised while restricting sugar and 
starch intake (at this point, hCG treatment stopped).  
Subjects  were  supervised  by  a  physician  with 
weekly health evaluations. The following parameters 
were  assessed  weekly:  body  composition,  including 
fat free mass (FFM), body fat (BF), total body water 
(TBW), intracellular/extracellular water, basal meta-
bolic rate and body mass index (BMI). Blood chemis-
try  parameters,  including  glucose,  cholesterols,  tri-
glycerides  and  circulating  CD34-positive  cells  were 
measured for nine subjects at the beginning and at the 
end of the study. Eight of the nine subjects who vol-
unteered for blood work were female: they ranged in 
age from thirty to sixty-five years old. The lone male 
was forty years old.  
Assay methods are described below. 
Body composition 
Body composition was measured by bioelectrical 
impedance analysis (BIA). The BIA is a non-invasive 
method  for  measuring  body  composition  through 
reactance and resistance, the two components of im-
pedance.  Bioelectrical  impedance  analysis  was  per-
formed  by  IMP  DF50  (Company  ImpediMed  Lim-
ited). The fat–free mass, body fat, basal metabolic rate, 
total  body  water,  extracellular  water,  intracellular Int. J. Med. Sci. 2011, 8 
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water and body mass index were determined for each 
participant  before  dieting  intervention  and  each  six 
days following intervention.  
 Assay of lipid profile 
A fasting serum was used for measurements of 
the lipid profile (total cholesterol, high-density lipo-
protein  cholesterol  (HDL),  low-density  lipoproteins 
(LDL),  triglycerides,  very  low-density  lipoproteins 
(VLDV)) and glucose, by established clinical labora-
tory tests. Cholesterol, HDL cholesterol, and triglyc-
erides were quantified by an auto-analyzer by an en-
zymatic method by using commercially available re-
agents  (Genzyme  Diagnostics).  LDL  cholesterol  (in 
fasting samples) was determined by calculation.  
CD34-positive cell measurements 
The analysis of the CD34 positive cells was per-
formed by adopting the gating strategy defined by the 
International  Society  of  Haematotherapy  and  Graft 
Engineering (ISHAGE) guidelines [27]. The method of 
the selection of stem/progenitor cells consisted from 
several  criteria.  Cells  were  selected  that  expressed 
CD34+  antigen,  did  not  express  CD45  antigen  and 
exhibited low side-angle light scatter characteristics of 
blasts  cells.  This  subpopulation  was  defined  as  of 
endothelial progenitor cells. Our decision to consid-
ered CD34 positive/CD45 negative circulating cells as 
“circulating  EPCs”  was  based  on  the  work  [28],  in 
which  blood–derived  cells  from  which  endothelial 
cells  in  culture  were  developed  were  described  as 
cells expressing CD34 antigen. It has been hypothe-
sized  that  endothelial  progenitor  cells  and  hemato-
poietic progenitor cells have common precursor, the 
hemangioblast  and  both  may  be  subsets  of  bone 
marrow-derived  progenitor  cells  expressing  CD34. 
Moreover,  recent  studies  demonstrate  that  CD34+ 
cells not expressing leukocyte antigen (CD45-) form 
endothelial colony-forming units and those express-
ing CD45 demonstrate hematopoietic properties [29].  
Specific cell surface staining was accomplished 
by  incubating  duplicate  samples  of  a  biological 
specimen (separated white blood cells) with two color 
CD45-FITC/CD34-PE  reagents  (Stem  kit  reagents, 
Beckman Coulter). In an additional test, the samples 
were stained with CD45-FITC/IsoClonic Control-PE 
reagent  to  check  the  non-specific  binding  of  the 
CD34-PE monoclonal antibody.  
Statistical analysis 
All data were analyzed by Systat software (Sys-
tat Inc) and KaleidaGraph software. Variables  were 
presented as mean values ±SD. Statistical analysis was 
done  by  linear  regression  model  and  paired 
non-parametrical test. Statistical significance was ac-
cepted  if  the  null  hypothesis  could  be  rejected  at 
p<0.05.  
Results  
The distributions of mass loss and fat mass loss 
by all subjects during the diet are shown in Figure 1.  
 
 
Figure 1. Distribution of the weight reduction and fat mass 
loss in all subjects participated in 36 days of the dieting 
program.  
 
 
Subjects lost between 2.5 and 17.2 kg during the 
study, with the most weight loss occurring in subjects 
who started out the heaviest. All subjects achieved a 
decrease in body mass index during the study. The 
average BMI for participants at the start of the study 
was 34.0 ± 7.2 (SD), while that after the study was 28.5 
± 6.7 (SD). Using a paired Student’s t-test, the differ-
ence is highly significant (p = 0.0004). This indicates 
that weight loss and changes in body composition did 
occur during the time course of the study.  
The weight reductions during the hypo-caloric 
diet and maintenance period for several patients are 
presented in Figure 2.  
Changes  in  body  composition  parameters  are 
summarized in Table 1.  
These  percentages  did  not  vary  systematically 
with the initial mass of the subjects. The decrease in 
body fat was substantial, and in most cases larger than 
the corresponding loss in lean mass. According to our 
data,  the average  percentage  loss  of  lean  mass  was 
5.7±4.7  and  the  average  change  in  body  fat  was Int. J. Med. Sci. 2011, 8 
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12.4±8.7. The percentage loss in body fat among the 
most subjects was significantly larger (p = 0.04) than 
the percentage loss in lean mass, suggesting an im-
provement in body composition. 
 
 
Figure 2. Examples of the effect of dieting and mainte-
nance periods on the weight loss for several participants.  
 
Table 1. Percent of decrease in total mass, fat free 
mass, intracellular/extracellular fluids and basal met-
abolic rate in subjects at the end of the study.  
 Parameter   Mean 
±SD 
Minimum 
value  
Maximum 
value  
Weight kg  8.1±3.3  1.8  16.9 
Total Body Water Liter  5.7±4.7  -3.2  16.1 
Total Body Water %  -2.6±4.1  -13.4  8.8 
Intracellular Fluid Liter  5.7±6.3  -11.3  15.7 
Intracellular Fluid %  0.0±3.0  -9.2  4.7 
Extracellular Fluid 
Liter 
5.8±4.6  -4.0  18.0 
Extracellular Fluid %  0.0±3.1  -5.1  9.2 
Fat Free Mass kg  5.7±4.7  -3.4  16.1 
Fat Free Mass %  -2.6±4.2  -13.6  8.8 
Fat Mass kg  12.4±8.7  -8.4  31.2 
Fat Mass %  4.7±8.3  -11.2  26.7 
Basal Metabolic Rate 
Mj 
3.9±2.0  0.0  10.1 
Basal Metabolic Rate 
CAL 
4.1±2.0  0.9  10.1 
Body Mass Index  8.1±2.0  2.0  16.9 
 
 
The treated subjects showed a decrease in their 
body mass index in an average of 8.1%±2.0%.  
Changes in total body water had inverse corre-
lation with changes in fat mass (r=0.86) and positive 
correlation with an increase in fat free mass (r=0.78). 
The level of intracellular water (ICW) correlated with 
fat  mass  and  fat  free  mass  changes  during  dieting. 
Intracellular water levels showed linear relation with 
fat free mass (r=0.9) and an inverse relation with fat 
mass (r=0.6). As intracellular fluid decreases due to 
different pathological conditions, the increase in in-
tracellular water suggests improvement in cell health 
and nutritional status. 
Basal  metabolic  rate  decreased  slightly  in  sub-
jects  during  their  treatment  (4.1%±2.0%).  The  per-
centage of the decrease in BMR correlated with the 
percentage of weight loss. The decreasing of BMR is 
not desirable for dieters; however, the BMR decrease 
seen in our study is modest.  
Statistically significant decreases in serum cho-
lesterol  levels  were  observed  during  the  treatment. 
Lipid profile data are summarized in Table 2.  
 
Table 2: Averaged blood chemistry parameters before 
and after the diet regiment are given. † indicates sig-
nificant difference between “Pre” and “Post” (p < 0.05 
using paired Student’s t-test). 
Lipid profile  Pre  Post 
Glucose (mg/dL)  91 ± 12  89 ± 7 
Cholesterol (mg/dL)  206 ± 36  177 ± 24 † 
Triglyceride (mg/dL)  119 ± 57  97 ± 36 
HDL Cholesterol (mg/dL)  52 ± 13  52 ± 10 
VLDL (mg/dL)  24 ± 11  19 ± 7 
LDL(mg/dL)  130 ± 29  106 ± 21 † 
Cholesterol / HDL  4.2 ± 1.2  3.5 ± 0.8 † 
LDL / HDL  2.7 ± 0.9  2.1 ± 0.7 † 
 
 
While  glucose  levels,  triglycerides,  very  low 
density lipoproteins (VLDL), and high density lipo-
proteins (HDL)  were not  affected, subjects saw  sig-
nificant  decreases  in  total  cholesterol,  low  density 
lipoprotein (LDL), and overall in ratios of cholesterol 
and  LDL  to  HDL.  These  variables  are  considered 
markers of cardiovascular disease. HDL protects ar-
teries  by  transporting  cholesterol  away,  while  LDL 
can be deposited on arterial walls and clog arteries. 
Changes in the level of cholesterol and LDL for all 
participants are shown in Figures 3, 4.  
For total cholesterol, the upper limit of the nor-
mal range is 200 mg/dL. Five of the subjects started 
the study above this threshold. All of these partici-
pants  experienced  cholesterol  decreases  during  the Int. J. Med. Sci. 2011, 8 
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diet treatment, with two returning completely to the 
normal range. The upper limit of the normal range for 
LDL is 100 mg/dL. Eight of the nine subjects started 
with above normal LDL, with three of them returning 
to normal levels during the treatment. Similar trends 
were  seen  with  the  cholesterol/HDL  ratio  (upper 
limit of normal being 5.0) and LDL/HDL (upper limit 
of normal being 3.6).  
 
 
 
Figure 3. The effect of the dieting program on the level of 
LDL in plasma.  
 
Figure 4. The effect of the dieting program on the level of 
cholesterol in plasma.  
 
Regression  analysis  was  conducted  between 
body  composition  parameters  and  lipid  profile  pa-
rameters.  The  mass  of  body  fat  (BF)  correlated 
strongly with the LDL to HDL ratio (r = 0.7), the cho-
lesterol to HDL ratio (r=0.68) and inversely with HDL 
(r = 0.43).  
Overall, these data indicated that the combina-
tion of a low calorie diet with hCG treatments reduced 
body fat as well as risk factors associated with cardi-
ovascular disease. 
Circulating CD34+ cells in peripheral blood, as a 
percentage of total leukocyte counts, were determined 
before and after the study. Weight loss was accompa-
nied by a significant improvement in the number of 
circulating progenitor cells (p < 0.01). On average, the 
enhancement of progenitor cell numbers was roughly 
seventy percent. Figure 5 shows how CD34+ cell lev-
els changed for each subject from the start to the end 
of the weight loss program. 
 
 
 
Figure 5. The improvement of CD34 positive cell number 
after diet.  
 
Figure  6  shows  the  correlation  between  circu-
lating CD34+ cell number (given here as the ratio of 
the percentage of cells after the diet to the percentage 
of cells before the diet) and the percentage of body fat 
lost by each subject during the study. 
A  correlation  also  exists  between  CD34+  cells 
and the proportion of fat free mass (r = 0.80) for each 
subject. The changes in body fat, and the changes in 
lipid profile parameters, coincide with improvements 
in circulatory progenitor cell numbers. 
To rule out the possibility that changing num-
bers of circulating CD34+ cells were simply part of an 
overall change in circulating white blood cells, we ran 
complete blood counts before and after treatment on 
the  nine  subjects  who  consented  to  blood  work. 
Changes in blood cell counts with treatment varied 
among the nine subjects, with five experiencing over-
all decreases (the maximum downward change was 
thirty  percent).  All  subjects  showed  a  decrease  in Int. J. Med. Sci. 2011, 8 
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lymphocyte counts (the decrease ranged from eight to 
thirty-five percent).  
The  normalization  of  CD34-positive  cell  num-
bers to total peripheral blood mononuclear cell num-
bers, demonstrated that the numbers of CD34-positive 
cells per micro liter increase by an average of forty 
percent. 
 
 
Figure 6. The ratio of CD34+ cells post diet to pre-diet as a 
function of percentage of body fat lost during the diet. 
 
Discussion  
Obesity is frequently associated with traditional 
cardiovascular  risk  factors  such  as  type  2  diabetes, 
hypertension,  dyslipidemia,  altered  coagula-
tion/fibrinolysis,  and  the  other  components  of  the 
metabolic syndrome [30]. All these abnormalities cre-
ate a state of constant and progressive damage to the 
vascular wall, manifested by a low-grade progressive 
inflammatory  process  and  endothelial  dysfunction 
[31, 32]. 
The  endothelial  cell  damages  due  to 
dyslipidemia  and  proinflammatory  cytokines  have 
been demonstrated in studies [33, 34]. Increased levels 
of  triglycerides  and  lipoproteins  in  obese  or  over-
weight  subjects  correlate  with  impairment  of  endo-
thelial function [35, 36]. Endothelial cell damage due 
to dyslipidemia plays a critical role in the develop-
ment and progression of atherosclerosis [37, 38].  
Given  the  role  of  endothelial  cell  damage  in 
obesity, our attention was turned to progenitor cells 
(CD34+/CD45-  cells).  These  cells  are  thought  to  be 
early  precursors  of  endothelial  progenitor  cells  and 
function to replenish aging as well as damaged en-
dothelial cells that line blood vessels. There is strong 
evidence of the role of circulating endothelial progen-
itor cells, including populations of CD34 positive cells 
presented in peripheral blood, in the maintenance of 
the  vasculature  and  neovascularization  [39,  40].  In 
several studies, the number of circulating EPCs and 
their migratory activity have been reported to be re-
duced in patients with risk factor for coronary artery 
disease and negatively correlated with the Framing-
ham cardiovascular risk score [41-43]. Therefore, in-
creasing  the  number  of  CD34-positive  cells  during 
treatment may provide an indicator of improvement 
of vascular health.  
In our study, we analyzed the effect of weight 
loss  on  the  improvement  of  lipid  profile  in  plasma 
and the increase of the level of CD34+/CD45- cells in 
circulation.  
The  data  from  our  study  demonstrated  that  a 
combination  of  a  very  low  calorie  diet  with  hCG 
treatments, and supplements, decreases overall mass 
and  body  fat  while  improving  lipid  profiles.  These 
benefits are accompanied by increases in circulating 
CD34+ cell numbers. 
The weight loss protocol, which we used in our 
study,  was  developed  in  the  1950s [23,  24].  Several 
studies  have  been  done  to  examine  the  efficacy  of 
hCG in treating obesity, with mixed results [44, 45]. 
The main question has been whether the addition of 
hCG to a very low calorie diet enhances weight loss 
compared to dieting alone. While most studies report 
weight loss due to dieting, they disagree as to whether 
factors  such  as  weight  reduction,  body  proportion, 
and  patient  reported  hunger  level  are  affected  by 
adding hCG to the diet. The issue is complicated by 
the fact that few of these studies were double-blind 
and placebo controlled. The experimental design used 
in the study [46] showed that the combination of the 
500 calorie per day diet and hCG injections offered a 
significant  benefit  to  dieters,  offering  increased 
weight loss and a decrease in hunger.  
In our study, we did not compare hCG and diet 
to diet alone, but our work shows the direction that 
such  a  study  should  take,  as  we  utilize  additional 
measures  such  as  body  composition  (fat  free  mass, 
body fat, total body water, BMI) for all participants 
and lipid profiles and circulating progenitor cell levels 
for a group of the patients to assess outcome. 
Our  study  provided  further  evidence  of  this 
linkage,  with  fat  loss  showing  a  strong  correlation Int. J. Med. Sci. 2011, 8 
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with changes in lipid profiles and increases in circu-
lating progenitor cell numbers. For participants who 
represented weight loss and fat mass loss, the maxi-
mum reduction in lipids that have effect on overall 
cardiovascular health was 29% for cholesterol, 38% for 
LDL, 26% for cholesterol to HDL ratio and 35% for 
LDL to HDL ratio.  
The  average  improvement  of  CD34+  cells  in 
circulation during dieting program was 69% ± 50%.  
In conclusion, the weight loss program analyzed 
in  our  study  resulted  in  the  improvement  of  the 
number of CD34+ cells in circulation and the decrease 
of the values of cardiovascular risk factors. According 
to our study, the circulating progenitor cell number 
can be improved by diet and weight loss. 
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